SOBI returns co-promote rights for hemophilia drugs to Pfizer

Swedish Orphan Biovitrum AB (SSE:SOBI) returned co-promotion rights in the Nordic region to Pfizer Inc. (NYSE:PFE) for hemophilia A drug ReFacto AF moroctocog alfa and hemophilia B drug BeneFIX. Swedish Orphan will receive $47.5 million for the return of the rights and will remain eligible for royalties on Pfizer's global sales of both products. For the first nine months of 2011, Swedish Orphan recorded SEK542 million ($81.7 million) in ReFacto AF revenue, which includes SEK374 million ($56.4 million) from manufacturing, SEK95 million ($14.3 million) from royalties and SEK73 million ($11 million) from co-promotion. Swedish Orphan will continue to supply the drug substance for ReFacto through 2020 under a separate agreement. The company does not break out revenue for BeneFIX. ...